Home > Publications database > Pediatric low-grade glioma: State-of-the-art and ongoing challenges. > print |
001 | 285301 | ||
005 | 20240229155107.0 | ||
024 | 7 | _ | |a 10.1093/neuonc/noad195 |2 doi |
024 | 7 | _ | |a pmid:37944912 |2 pmid |
024 | 7 | _ | |a 1522-8517 |2 ISSN |
024 | 7 | _ | |a 1523-5866 |2 ISSN |
024 | 7 | _ | |a altmetric:156263259 |2 altmetric |
037 | _ | _ | |a DKFZ-2023-02322 |
041 | _ | _ | |a English |
082 | _ | _ | |a 610 |
100 | 1 | _ | |a Fangusaro, Jason |0 0000-0003-3099-5259 |b 0 |
245 | _ | _ | |a Pediatric low-grade glioma: State-of-the-art and ongoing challenges. |
260 | _ | _ | |a Oxford |c 2024 |b Oxford Univ. Press |
336 | 7 | _ | |a article |2 DRIVER |
336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1705658337_22126 |2 PUB:(DE-HGF) |
336 | 7 | _ | |a ARTICLE |2 BibTeX |
336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
500 | _ | _ | |a 2024 Jan 5;26(1):25-37 |
520 | _ | _ | |a The most common childhood central nervous system (CNS) tumor is pediatric low-grade glioma (pLGG), representing 30%-40% of all CNS tumors in children. Although there is high associated morbidity, tumor-related mortality is relatively rare. pLGG is now conceptualized as a chronic disease, underscoring the importance of functional outcomes and quality-of-life measures. A wealth of data has emerged about these tumors, including a better understanding of their natural history and their molecular drivers, paving the way for the use of targeted inhibitors. While these treatments have heralded tremendous promise, challenges remain about how to best optimize their use, and the long-term toxicities associated with these inhibitors remain unknown. The International Pediatric Low-Grade Glioma Coalition (iPLGGc) is a global group of physicians and scientists with expertise in pLGG focused on addressing key pLGG issues. Here, the iPLGGc provides an overview of the current state-of-the-art in pLGG, including epidemiology, histology, molecular landscape, treatment paradigms, survival outcomes, functional outcomes, imaging response, and ongoing challenges. This paper also serves as an introduction to 3 other pLGG manuscripts on (1) pLGG preclinical models, (2) consensus framework for conducting early-phase clinical trials in pLGG, and (3) pLGG resistance, rebound, and recurrence. |
536 | _ | _ | |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312) |0 G:(DE-HGF)POF4-312 |c POF4-312 |f POF IV |x 0 |
588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
650 | _ | 7 | |a MAPK/ERK pathway |2 Other |
650 | _ | 7 | |a overview |2 Other |
650 | _ | 7 | |a pediatric low-grade glioma |2 Other |
650 | _ | 7 | |a targeted therapy |2 Other |
700 | 1 | _ | |a Jones, David T |0 P:(DE-He78)551bb92841f634070997aa168d818492 |b 1 |u dkfz |
700 | 1 | _ | |a Packer, Roger J |b 2 |
700 | 1 | _ | |a Gutmann, David H |b 3 |
700 | 1 | _ | |a Milde, Till |0 P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f |b 4 |u dkfz |
700 | 1 | _ | |a Witt, Olaf |0 P:(DE-He78)143af26de9d57bf624771616318aaf7c |b 5 |u dkfz |
700 | 1 | _ | |a Mueller, Sabine |b 6 |
700 | 1 | _ | |a J Fisher, Michael |b 7 |
700 | 1 | _ | |a Hansford, Jordan R |b 8 |
700 | 1 | _ | |a Tabori, Uri |0 0000-0002-5019-2683 |b 9 |
700 | 1 | _ | |a Hargrave, Darren |b 10 |
700 | 1 | _ | |a Bandopadhayay, Pratiti |0 0000-0002-4175-4760 |b 11 |
773 | _ | _ | |a 10.1093/neuonc/noad195 |g p. noad195 |0 PERI:(DE-600)2094060-9 |n 1 |p 25-37 |t Neuro-Oncology |v 26 |y 2024 |x 1522-8517 |
909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:285301 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)551bb92841f634070997aa168d818492 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)143af26de9d57bf624771616318aaf7c |
913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-312 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Funktionelle und strukturelle Genomforschung |x 0 |
914 | 1 | _ | |y 2023 |
915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-10-24 |w ger |
915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NEURO-ONCOLOGY : 2022 |d 2023-10-24 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-24 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-24 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-10-24 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-24 |
915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-24 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-24 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-24 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-24 |
915 | _ | _ | |a IF >= 15 |0 StatID:(DE-HGF)9915 |2 StatID |b NEURO-ONCOLOGY : 2022 |d 2023-10-24 |
920 | 1 | _ | |0 I:(DE-He78)B360-20160331 |k B360 |l Pädiatische Gliomforschung |x 0 |
920 | 1 | _ | |0 I:(DE-He78)B310-20160331 |k B310 |l KKE Pädiatrische Onkologie |x 1 |
920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 2 |
980 | _ | _ | |a journal |
980 | _ | _ | |a VDB |
980 | _ | _ | |a I:(DE-He78)B360-20160331 |
980 | _ | _ | |a I:(DE-He78)B310-20160331 |
980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
980 | _ | _ | |a UNRESTRICTED |
Library | Collection | CLSMajor | CLSMinor | Language | Author |
---|